Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium

(2011) Lynda M. Vrooman et al.   EUROPEAN JOURNAL OF CANCER

Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study

(2010) Christine Mauz-Körholz et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

(2010) Steven E Lipshultz et al.   LANCET ONCOLOGY

Should anthracyclines and dexrazoxane be used for children with cancer?

(2010) Elvira C van Dalen et al.   LANCET ONCOLOGY

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425

(2009) C. L. Schwartz et al.   BLOOD

Treatment of Pediatric Hodgkin Lymphoma

(2008) Michael R. Olson et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY